Abstract Library

#3129 Colorectal NECs and MANECs: A monocenter pilot retrospective analysis

Introduction: Poorly-differentiated neuroendocrine carcinomas (NECs) and mixed adeno-neuroendocrine carcinomas (MANECs) are rare and aggressive neoplasms whose tumorigenesis pathways are still unknown and clinical management not universally shared.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Laffi A, Spada F, Ranghiero A, Pisa E, Barberis M,

Keywords: mutational, genetic, neuroendocrine, NEC, MANEC, carcinogenesis, colorectal,

#2939 Prognostic Evaluation for Gastroenteropancreatic NEC: AJCC or ENETS Staging Classification or Others?

Introduction: For poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), American Joint Committee on Cancer (AJCC) recommends to use a classification different from that for well-differentiated neuroendocrine tumor. However, this is not adopted by European Neuroendocrine Tumor Society (ENETS) staging classification.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zhang Y, Chen L, Lin Z, Zhang T, Chen M,

Keywords: gastroenteropancreatic neuroendocrine carcinoma, prognosis, staging,

#2740 Long-Term Complete Response in Metastatic Poorly-Differentiated Neuroendocrine Rectal Carcinoma with Multimodal Approach. A Case Report

Introduction: Rectal neuroendocrine carcinomas (NEC) are extremely rare and account for less than 1% of colorectal malignancies.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Della Torre S

Authors: Lombardi P, Grandi S, Marinelli M, Manara M, Della Torre S,

Keywords: rectal nec, net, chemotherapy, metastatic disease,

#2683 Clinicopathological Features and Prognostic Analysis of 227 Cases with Well-Differentiated Gastric Neuroendocrine Tumors

Introduction: Gastric neuroendocrine neoplasms (g-NENs) are a group of rare tumors with a strong heterogeneity, subdivided as well-differentiated neuroendocrine tumors (NETs, type 1-3 g-NETs) and poorly-differentiated neuroendocrine carcinoma(NECs). WHO classification(2019) for digestive system tumours has carried out a new classification and grading criteria for NENs of the gastrointestinal tract recently, there is very few relevant clinical data based on this new classification, especially for gastric NETs(g-NETs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Li Y, Tan H, Jie C, Jie L, Pan Z,

Keywords: clinicopathological features, prognostic analysis, well-differentiated gastric neuroendocrine tumors, grade, type,

#2107 Carboplatin-Etoposide Chemotherapy (CB-ET) for Patients Diagnosed with Advanced Extra-Pulmonary (EP) Poorly Differentiated (PD) Neuroendocrine Carcinoma (NEC): Findings from a European Neuroendocrine Tumour Society Centre of Excellence

Introduction: Carboplatin-Etoposide is a first-line option for patients (pts) with advanced EP-PD-NEC. Data from randomised trials are lacking

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Frizziero M

Authors: Frizziero M, Lamarca A, Kordatou Z, Barriuso J, Nuttall C,

Keywords: carboplatin-etoposide, poorly-differentiated extra-pulmonary neuroendocrine carcinoma, activity, efficacy, safety,